← back to search

Cynthia Wetmore

American Society of Hematology ·
Area of research
Genetics · Molecular Biology
Research interest
Research interests include Glioma Diagnosis and Treatment, Hedgehog Signaling Pathway Studies, Neuroblastoma Research and Treatments, and Nerve injury and regeneration.
h-index
45
citations
11,219
works
153
NIH funding
primary concept
email

Recent publications

Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor
Neuro-Oncology 2022cited by 28position: middledoi
Long-term Follow-up Care for Childhood, Adolescent, and Young Adult Cancer Survivors
PEDIATRICS 2021cited by 155position: middledoi
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)
Pediatric Blood & Cancer 2021cited by 36position: lastdoi
Fertility Preservation for Pediatric and Adolescent Patients With Cancer: Medical and Ethical Considerations
PEDIATRICS 2020cited by 94position: middledoi
Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features
Acta Neuropathologica 2020cited by 44position: middledoi
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors
Pediatric Blood & Cancer 2019cited by 31position: middledoi
In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells
BMC Cancer 2019cited by 27position: middledoi
Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia
Blood 2016cited by 86position: middledoi
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high‐grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021
Cancer Medicine 2016cited by 67position: firstdoi
Reirradiation of recurrent medulloblastoma: Does clinical benefit outweigh risk for toxicity?
Cancer 2014cited by 76position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Carl E. Allen · Baylor College of Medicine2 papers (2020–2021)Jeffrey H. Lipton · Princess Margaret Cancer Centre2 papers (2020–2021)Rachel Tanos · Emory University2 papers (2016–2019)Amar Gajjar · Mills Peninsula Health Services2 papers (2014–2016)Amber M. Yates · Texas Children's Hospital2 papers (2020–2021)Zora R. Rogers · Southwestern Medical Center2 papers (2020–2021)Hope P. Wilson · University of Alabama at Birmingham2 papers (2020–2021)Kelly C. Goldsmith · Emory University2 papers (2016–2019)R.J. Arceci · University of Arizona1 papers (2019–2019)Sigal Klipstein · American Society for Reproductive Medicine1 papers (2020–2020) · 1 papers (2020–2020) · 1 papers (2016–2016)Jacqueline Casillas · University of California, Los Angeles1 papers (2021–2021)Nigel J. Waters · Novartis (Switzerland)1 papers (2016–2016)Benjamin Watkins · Aflac (United States)1 papers (2019–2019)Robert Macauley · University of Vermont1 papers (2020–2020)Tobey J. MacDonald · Emory University1 papers (2019–2019)Patrick A. Brown · Haemonetics (United States)1 papers (2016–2016)Charles G. Minard · Baylor College of Medicine1 papers (2021–2021) · 1 papers (2021–2021)